PD-L1 as a biomarker of response to immune-checkpoint inhibitors
DB Doroshow, S Bhalla, MB Beasley… - Nature reviews Clinical …, 2021 - nature.com
Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …
Dostarlimab: a review
B Costa, N Vale - Biomolecules, 2022 - mdpi.com
Dostarlimab (JEMPERLI) is a PD-1 monoclonal antibody for the treatment of adult patients,
with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has …
with mismatch repair deficient (dMMR), recurrent or advanced endometrial cancer that has …
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
The future of cancer immunotherapy: DNA vaccines leading the way
A Pandya, Y Shah, N Kothari, H Postwala, A Shah… - Medical Oncology, 2023 - Springer
Immuno-oncology has revolutionized cancer treatment and has opened up new
opportunities for developing vaccination methods. DNA-based cancer vaccines have …
opportunities for developing vaccination methods. DNA-based cancer vaccines have …
The evolving landscape of anatomic pathology
Anatomic pathology has changed dramatically in recent years. Although the microscopic
assessment of tissues and cells is and will remain the mainstay of cancer diagnosis …
assessment of tissues and cells is and will remain the mainstay of cancer diagnosis …
PD-1 inhibitor combined with radiotherapy and GM-CSF (PRaG) in patients with metastatic solid tumors: an open-label phase II study
Y Kong, X Zhao, M Xu, J Pan, Y Ma, L Zou… - Frontiers in …, 2022 - frontiersin.org
Patients with metastatic cancer refractory to standard systemic therapies have a poor
prognosis and few therapeutic options. Radiotherapy can shape the tumor …
prognosis and few therapeutic options. Radiotherapy can shape the tumor …
[HTML][HTML] Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast …
H Zhang, L Chen, Y Zhao, N Luo, J Shi, S Xu… - Asian journal of …, 2023 - Elsevier
Cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cells in the
tumor microenvironment which mediate desmoplastic response and are the primary driver …
tumor microenvironment which mediate desmoplastic response and are the primary driver …
Clinicopathologic and genomic landscape of non-small cell lung cancer brain metastases
Background In patients with non-small cell lung cancer (NSCLC), 10%-40% will eventually
develop brain metastases. We present the clinicopathologic, genomic, and biomarker …
develop brain metastases. We present the clinicopathologic, genomic, and biomarker …
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy
EM Ebot, DL Duncan, K Tolba, D Fabrizio… - NPJ Precision …, 2022 - nature.com
NCCN guidelines for first-line treatment of advanced non-squamous non-small-cell lung
cancer (NSCLC) patients without targetable driver alterations includes either …
cancer (NSCLC) patients without targetable driver alterations includes either …
Immunotherapy for management of thymic epithelial tumors: a double-edged sword
M Ballman, C Zhao, MJ McAdams, A Rajan - Cancers, 2022 - mdpi.com
Simple Summary Immunotherapy has a rapidly expanding role for the treatment of several
cancers due to durable clinical activity and favorable tolerability. However, the unique …
cancers due to durable clinical activity and favorable tolerability. However, the unique …